Acasti announces wuxi clinical as cro to conduct strive-on pivotal phase 3 safety trial for gtx-104 in asah patients

Strive-on is a pivotal phase 3 trial of gtx-104 to evaluate its comparable safety and tolerability profile relative to oral nimodipine in patients hospitalized with asah laval, qb, july 10, 2023 /prnewswire/ -- acasti pharma inc. (nasdaq: acst) ("acasti" or the "company"), a late-stage, biopharma company advancing gtx-104, today announced wuxi clinical development, inc. ("wuxi clinical"), a wholly owned subsidiary of wuxi apptec, a global contract research organization (cro), will conduct acasti's strive-on phase 3 safety trial for gtx-104. gtx-104 is acasti's novel, injectable nimodipine formulation for intravenous infusion (iv) that addresses high, unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage (asah).
ACST Ratings Summary
ACST Quant Ranking